Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections

摘要

Background: Clostridium difficile infection (CDI) is the most frequent cause of nosocomial diarrhoea in adults. Cancer patients, in particular, are at a higher risk for CDI. Limited clinical data exist regarding the use of tigecycline for the treatment of CDI, especially in patients with oncologic and haematologic malignancies.